These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 486615)

  • 1. Neurolepticlike actions of l-methadone: effect on mescaline-induced altered behavior and on tissue levels of mescaline in mice.
    Shah NS; Hudnall SD; May D; Eargle D; Yates J
    Biol Psychiatry; 1979 Aug; 14(4):587-94. PubMed ID: 486615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of mescaline with phenothiazines: effect on behavior, body temperature, and tissue levels of hallucinogen in mice.
    Shah NS; Jacobs JR; Jones JT; Hedden MP
    Biol Psychiatry; 1975 Oct; 10(5):561-73. PubMed ID: 241433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scratching response induced in mice by mescaline and related amphetamine derivatives.
    Kulkarni AS
    Biol Psychiatry; 1973 Apr; 6(2):177-80. PubMed ID: 4709133
    [No Abstract]   [Full Text] [Related]  

  • 4. On the mechanism of antidepressant-like action of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral characterization of morphine effects on motor activity in mice.
    Patti CL; Frussa-Filho R; Silva RH; Carvalho RC; Kameda SR; Takatsu-Coleman AL; Cunha JL; Abílio VC
    Pharmacol Biochem Behav; 2005 Aug; 81(4):923-7. PubMed ID: 16083952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A; Kulkarni SK
    Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of chlorpromazine and haloperidol on the disposition of mescaline-14C in mice.
    Shah NS; Shah KR; Lawrence RS; Neely AE
    J Pharmacol Exp Ther; 1973 Aug; 186(2):297-304. PubMed ID: 4719782
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological vs. clinical physiognomy of neuroleptics, with special reference to their sedative and antipsychotic effects.
    Nielsen IM
    Acta Psychiatr Belg; 1974 Sep; 74(5):473-84. PubMed ID: 4471027
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of psychotropic drugs and beta-diethylaminoethyl-diphenylpropylacetate (SKF 525-A) on mescaline-induced behavior and on tissue levels of mescaline in mice.
    Shah NS
    Biochem Pharmacol; 1976 Mar; 25(5):591-7. PubMed ID: 8055
    [No Abstract]   [Full Text] [Related]  

  • 10. Brain levels of serotonin (5-HT) and norepinephrine (NE) during mescaline-induced behavior in mice.
    Shah NS
    Res Commun Chem Pathol Pharmacol; 1973 Jan; 5(1):201-4. PubMed ID: 4686103
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection.
    Geber WF; Lefkowitz SS; Hung CY
    Arch Int Pharmacodyn Ther; 1975 Apr; 214(2):322-7. PubMed ID: 50766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute effects of mescaline HCl on behavior, resistance, and endocrine function of male mice.
    Sackler AM; Weltman AS; Johnson L
    Exp Med Surg; 1971; 29(1):118-27. PubMed ID: 5147592
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice.
    Lautar SL; Rojas C; Slusher BS; Wozniak KM; Wu Y; Thomas AG; Waldon D; Li W; Ferraris D; Belyakov S
    Brain Res; 2005 Jun; 1048(1-2):177-84. PubMed ID: 15925329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.
    Janssen PA; Niemegeers CJ; Schellekens KH; Lenaerts FM
    Arzneimittelforschung; 1967 Jul; 17(7):841-54. PubMed ID: 5632842
    [No Abstract]   [Full Text] [Related]  

  • 16. Cumulative alterations in rat behavior during continuous administration of LSD or mescaline: absence of tolerance?
    Ellison G; Ring M; Ross D; Axelrood B
    Biol Psychiatry; 1980 Feb; 15(1):95-102. PubMed ID: 7357060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid and nonopioid behavioral effects of methadone isomers.
    Leander JD; McCleary PE
    J Pharmacol Exp Ther; 1982 Mar; 220(3):592-6. PubMed ID: 7062269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Behavioral and neuopharmacological effects of flupentixol].
    Ueki S; Ogawa N; Watanabe S; Gomita Y; Araki Y
    Igaku Kenkyu; 1971 Jul; 41(5):404-40. PubMed ID: 5165980
    [No Abstract]   [Full Text] [Related]  

  • 20. Behavioral characterization of the new potent nonselective dopamine agonist pergolide.
    Helton DR; Modlin DL; Williams PD
    Arzneimittelforschung; 1992 Jul; 42(7):885-90. PubMed ID: 1418051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.